Does the media refer more to KRYS or RARE?

In the previous week, Krystal Biotech and Krystal Biotech both had 6 articles in the media. Ultragenyx Pharmaceutical's average media sentiment score of 0.79 beat Krystal Biotech's score of 0.45 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NUVL or RARE?

In the previous week, Nuvalent had 5 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 11 mentions for Nuvalent and 6 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.79 beat Nuvalent's score of 0.15 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IBRX or RARE?

In the previous week, ImmunityBio had 1 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 7 mentions for ImmunityBio and 6 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.79 beat ImmunityBio's score of 0.45 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RARE or QGEN?

In the previous week, Qiagen had 12 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 18 mentions for Qiagen and 6 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.79 beat Qiagen's score of -0.43 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IMVT or RARE?

In the previous week, Immunovant had 2 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 8 mentions for Immunovant and 6 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.79 beat Immunovant's score of 0.35 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ultragenyx Pharmaceutical (RARE) Competitors

$22.41 +0.63 (+2.89%)

Closing price 04:00 PM Eastern

Extended Trading

$22.52 +0.11 (+0.51%)

As of 06:19 PM Eastern

Compare

RARE vs. KRYS, NUVL, IBRX, QGEN, and IMVT

Should you buy Ultragenyx Pharmaceutical stock or one of its competitors? MarketBeat compares Ultragenyx Pharmaceutical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ultragenyx Pharmaceutical include Krystal Biotech (KRYS), Nuvalent (NUVL), ImmunityBio (IBRX), Qiagen (QGEN), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry.

How does Ultragenyx Pharmaceutical compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Krystal Biotech has a net margin of 53.92% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Krystal Biotech's return on equity of 19.25% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

In the previous week, Krystal Biotech and Krystal Biotech both had 6 articles in the media. Ultragenyx Pharmaceutical's average media sentiment score of 0.79 beat Krystal Biotech's score of 0.45 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

Krystal Biotech presently has a consensus price target of $324.11, indicating a potential upside of 7.39%. Ultragenyx Pharmaceutical has a consensus price target of $59.56, indicating a potential upside of 165.79%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

Krystal Biotech has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	22.87	$204.83M	$7.48	40.35
Ultragenyx Pharmaceutical	$673M	3.28	-$575M	-$6.11	N/A

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Krystal Biotech beats Ultragenyx Pharmaceutical on 10 of the 16 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

In the previous week, Nuvalent had 5 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 11 mentions for Nuvalent and 6 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.79 beat Nuvalent's score of 0.15 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvalent has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Nuvalent's return on equity of -40.11% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

Nuvalent presently has a consensus price target of $141.24, suggesting a potential upside of 56.61%. Ultragenyx Pharmaceutical has a consensus price target of $59.56, suggesting a potential upside of 165.79%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.94
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

Nuvalent has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Nuvalent is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Ultragenyx Pharmaceutical	$673M	3.28	-$575M	-$6.11	N/A

Nuvalent has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

97.3% of Nuvalent shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 5.0% of Nuvalent shares are held by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Nuvalent beats Ultragenyx Pharmaceutical on 9 of the 15 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

ImmunityBio currently has a consensus target price of $14.20, suggesting a potential upside of 97.77%. Ultragenyx Pharmaceutical has a consensus target price of $59.56, suggesting a potential upside of 165.79%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, ImmunityBio had 1 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 7 mentions for ImmunityBio and 6 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.79 beat ImmunityBio's score of 0.45 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmunityBio has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. ImmunityBio is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	66.38	-$351.40M	-$0.85	N/A
Ultragenyx Pharmaceutical	$673M	3.28	-$575M	-$6.11	N/A

ImmunityBio has a beta of 0.03, suggesting that its share price is 97% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

Ultragenyx Pharmaceutical has a net margin of -91.03% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 69.5% of ImmunityBio shares are held by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Ultragenyx Pharmaceutical beats ImmunityBio on 11 of the 17 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Qiagen?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Qiagen had 12 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 18 mentions for Qiagen and 6 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.79 beat Qiagen's score of -0.43 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Qiagen has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	3.28	-$575M	-$6.11	N/A
Qiagen	$2.09B	3.59	$424.88M	$1.91	19.08

Ultragenyx Pharmaceutical presently has a consensus price target of $59.56, indicating a potential upside of 165.79%. Qiagen has a consensus price target of $44.98, indicating a potential upside of 23.41%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

Qiagen has a net margin of 19.16% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Qiagen's return on equity of 14.40% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Qiagen	19.16%	14.40%	8.40%

Ultragenyx Pharmaceutical has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Summary

Qiagen beats Ultragenyx Pharmaceutical on 11 of the 16 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Immunovant presently has a consensus price target of $37.33, indicating a potential upside of 19.85%. Ultragenyx Pharmaceutical has a consensus price target of $59.56, indicating a potential upside of 165.79%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

Immunovant has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

Immunovant has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Immunovant is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Ultragenyx Pharmaceutical	$673M	3.28	-$575M	-$6.11	N/A

Immunovant has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Immunovant's return on equity of -65.66% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

In the previous week, Immunovant had 2 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 8 mentions for Immunovant and 6 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.79 beat Immunovant's score of 0.35 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Ultragenyx Pharmaceutical beats Immunovant on 10 of the 16 factors compared between the two stocks.

Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RARE vs. The Competition

Export

Metric	Ultragenyx Pharmaceutical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.21B	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-3.67	17.93	22.30	24.19
Price / Sales	3.28	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	-27.00	6.63	9.84	6.72
Net Income	-$575M	$24.20M	$3.57B	$337.19M
7 Day Performance	-4.19%	-3.24%	-1.16%	0.48%
1 Month Performance	-9.53%	0.53%	3.85%	5.07%
1 Year Performance	-38.43%	47.24%	27.40%	34.25%

Ultragenyx Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RARE Ultragenyx Pharmaceutical	2.8137 of 5 stars	$22.41 +2.9%	$59.56 +165.8%	-39.7%	$2.21B	$673M	N/A	1,371	Positive News Insider Trade
KRYS Krystal Biotech	3.2722 of 5 stars	$299.45 flat	$324.11 +8.2%	+133.9%	$8.83B	$389.13M	40.03	210	Analyst Forecast
NUVL Nuvalent	3.439 of 5 stars	$102.12 flat	$140.29 +37.4%	+18.4%	$8.07B	N/A	N/A	40	News Coverage Analyst Forecast Insider Trade
IBRX ImmunityBio	2.4312 of 5 stars	$7.22 flat	$14.20 +96.7%	+170.8%	$7.56B	$113.29M	N/A	590	Analyst Forecast
QGEN Qiagen	4.1509 of 5 stars	$35.23 +0.2%	$44.98 +27.7%	-24.4%	$7.25B	$2.09B	18.40	5,654

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RARE) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ultragenyx Pharmaceutical (RARE) Competitors

RARE vs. KRYS, NUVL, IBRX, QGEN, and IMVT

How does Ultragenyx Pharmaceutical compare to Krystal Biotech?

Summary

How does Ultragenyx Pharmaceutical compare to Nuvalent?

Summary

How does Ultragenyx Pharmaceutical compare to ImmunityBio?

Summary

How does Ultragenyx Pharmaceutical compare to Qiagen?

Summary

How does Ultragenyx Pharmaceutical compare to Immunovant?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RARE vs. The Competition

Ultragenyx Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ultragenyx Pharmaceutical (RARE) Competitors

RARE vs. KRYS, NUVL, IBRX, QGEN, and IMVT

How does Ultragenyx Pharmaceutical compare to Krystal Biotech?

Is KRYS or RARE more profitable?

Does the media refer more to KRYS or RARE?

Which has more risk and volatility, KRYS or RARE?

Do analysts prefer KRYS or RARE?

Which has better valuation and earnings, KRYS or RARE?

Do insiders & institutionals believe in KRYS or RARE?

Summary

How does Ultragenyx Pharmaceutical compare to Nuvalent?

Does the media refer more to NUVL or RARE?

Is NUVL or RARE more profitable?

Do analysts rate NUVL or RARE?

Which has preferable earnings and valuation, NUVL or RARE?

Which has more risk & volatility, NUVL or RARE?

Do insiders & institutionals hold more shares of NUVL or RARE?

Summary

How does Ultragenyx Pharmaceutical compare to ImmunityBio?

Do analysts prefer IBRX or RARE?

Does the media favor IBRX or RARE?

Which has preferable earnings and valuation, IBRX or RARE?

Which has more volatility and risk, IBRX or RARE?

Is IBRX or RARE more profitable?

Do insiders and institutionals have more ownership in IBRX or RARE?

Summary

How does Ultragenyx Pharmaceutical compare to Qiagen?

Do insiders and institutionals hold more shares of RARE or QGEN?

Does the media refer more to RARE or QGEN?

Which has higher valuation and earnings, RARE or QGEN?

Do analysts rate RARE or QGEN?

Is RARE or QGEN more profitable?

Which has more risk and volatility, RARE or QGEN?

Summary

How does Ultragenyx Pharmaceutical compare to Immunovant?

Do analysts recommend IMVT or RARE?

Which has more risk & volatility, IMVT or RARE?

Which has higher valuation and earnings, IMVT or RARE?

Is IMVT or RARE more profitable?

Does the media favor IMVT or RARE?

Do institutionals and insiders believe in IMVT or RARE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RARE vs. The Competition

Ultragenyx Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools